Literature DB >> 16323120

Vancomycin: a history.

Donald P Levine1.   

Abstract

Vancomycin became available for clinical use >50 years ago but was soon discarded in favor of other antibiotics that were deemed to be more efficacious and less toxic. The advent of pseudomembranous enterocolitis, coupled with the spread of methicillin-resistant Staphylococcus aureus, led to a resurgence in the use of vancomycin. Almost immediately, concerns arose with regard to its therapeutic utility. In addition, resistance to vancomycin developed, first in enterococci and later in staphylococci. Several types of resistance have now been identified, each with a unique effect on infections treated with vancomycin. Recent studies have rekindled interest in the best way to administer the antibiotic. The findings of future studies may result in a return to measuring levels of vancomycin in serum, to assure a successful therapeutic outcome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16323120     DOI: 10.1086/491709

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  188 in total

1.  Vancomycin C-Terminus Guanidine Modifications and Further Insights into an Added Mechanism of Action Imparted by a Peripheral Structural Modification.

Authors:  Zhi-Chen Wu; Michael D Cameron; Dale L Boger
Journal:  ACS Infect Dis       Date:  2020-07-14       Impact factor: 5.084

Review 2.  Vancomycin: a review of population pharmacokinetic analyses.

Authors:  Amélie Marsot; Audrey Boulamery; Bernard Bruguerolle; Nicolas Simon
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

Review 3.  Synthetic cell surface receptors for delivery of therapeutics and probes.

Authors:  David Hymel; Blake R Peterson
Journal:  Adv Drug Deliv Rev       Date:  2012-02-25       Impact factor: 15.470

4.  Biopsy-proven vancomycin-associated interstitial nephritis and acute tubular necrosis.

Authors:  Naing Lin Htike; Jerome Santoro; Brett Gilbert; I Bruce Elfenbein; Geoffrey Teehan
Journal:  Clin Exp Nephrol       Date:  2011-11-16       Impact factor: 2.801

Review 5.  Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review.

Authors:  Sepideh Elyasi; Hossein Khalili; Simin Dashti-Khavidaki; Amirhooshang Mohammadpour
Journal:  Eur J Clin Pharmacol       Date:  2012-03-13       Impact factor: 2.953

6.  Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design.

Authors:  Konstantinos Z Vardakas; Michael N Mavros; Nikolaos Roussos; Matthew E Falagas
Journal:  Mayo Clin Proc       Date:  2012-04       Impact factor: 7.616

7.  Vancomycin-Associated Cast Nephropathy.

Authors:  Yosu Luque; Kevin Louis; Chantal Jouanneau; Sandrine Placier; Emmanuel Esteve; Dominique Bazin; Eric Rondeau; Emmanuel Letavernier; Alice Wolfromm; Clément Gosset; Anna Boueilh; Maren Burbach; Perrine Frère; Marie-Christine Verpont; Sophie Vandermeersch; Dominique Langui; Michel Daudon; Vincent Frochot; Laurent Mesnard
Journal:  J Am Soc Nephrol       Date:  2017-01-12       Impact factor: 10.121

8.  Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD.

Authors:  Kevin E Chan; H Shaw Warren; Ravi I Thadhani; David J R Steele; Jeffrey L Hymes; Franklin W Maddux; Raymond M Hakim
Journal:  J Am Soc Nephrol       Date:  2012-08-16       Impact factor: 10.121

9.  Trichlorination of a Teicoplanin-Type Glycopeptide Antibiotic by the Halogenase StaI Evades Resistance.

Authors:  Grace Yim; Wenliang Wang; Andrew C Pawlowski; Gerard D Wright
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

Review 10.  Total Syntheses of Vancomycin-Related Glycopeptide Antibiotics and Key Analogues.

Authors:  Akinori Okano; Nicholas A Isley; Dale L Boger
Journal:  Chem Rev       Date:  2017-04-24       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.